Related Experiment Video
Updated: Feb 1, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
Systemic Administered mRNA as Therapy for Metabolic Diseases
Hervé Puy1, Jean-Charles Deybach1, Laurent Gouya1
1UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, Université Paris Diderot, F-75018 Paris, France; Assistance Publique-Hôpitaux de Paris, HUPNVS Centre Français des Porphyries, Hôpital Louis Mourier, 178 Rue des Renouillers, F-92701 Colombes, France; Laboratory of Excellence Gr-Ex, 75015 Paris, France.
Messenger RNA (mRNA) therapy shows promise for treating diseases. Intravenous delivery of human porphobilinogen deaminase (PBGD) mRNA effectively replaced defective PBGD protein in preclinical models of acute intermittent porphyria.
Area of Science:
- Biotechnology
- Genetics
- Medical Research
Background:
- Messenger RNA (mRNA) holds significant therapeutic potential for protein replacement therapies.
- Acute intermittent porphyria (AIP) is a genetic disorder caused by a deficiency in the porphobilinogen deaminase (PBGD) enzyme.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous delivery of human PBGD mRNA for treating AIP.
- To assess the potential of mRNA therapy for genetic disorders.
Main Methods:
- Intravenous administration of human PBGD mRNA in preclinical models of AIP.
- Monitoring of PBGD protein levels and disease markers post-administration.
Main Results:
- Successful restoration of functional PBGD protein levels in the liver.
- Demonstrated efficacy and safety of the mRNA-based therapeutic approach.
Conclusions:
- Intravenous mRNA delivery is a viable strategy for treating acute intermittent porphyria.
- This study supports mRNA as a promising platform for protein replacement therapies in genetic diseases.
Related Concept Videos
Regulated mRNA Transport
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Nuclear Export of mRNA
What is Metabolism?
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

